Vensica Medical

Executive Summary

Vensica Medical is an Israeli med-tech company pioneering a needle-free ultrasound-based drug delivery platform called Vibe, designed for localized bladder therapy. Its lead product, ViXe, combines Vibe with FDA-approved Botulinum Toxin A (Xeomin®) to treat overactive bladder (OAB) and other urological conditions. By enabling non-invasive, targeted drug administration, ViXe aims to improve patient compliance and reduce side effects compared to traditional intravesical injections or oral medications. The company has raised $30 million and is currently in Phase 2 clinical development. With a strong intellectual property portfolio and a clear unmet need in OAB therapy, Vensica Medical is positioned to disrupt the urology market. Its innovative approach addresses a significant patient population seeking minimally invasive alternatives, and the technology has potential to expand into other bladder disorders, such as interstitial cystitis and neurogenic bladder. The company's progress in clinical trials and its ability to secure regulatory approvals will be critical to its commercial success.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 top-line results for ViXe in overactive bladder65% success
• Q4 2026FDA pre-IND meeting or Phase 2/3 design guidance75% success
• H2 2026Strategic partnership or licensing deal for Vibe platform60% success